Medinice

Medinice EV/EBIT

The EV/EBIT (Enterprise Value to EBIT) of Medinice (ICE.WA) as of Nov 3, 2026 is -63.03. In the previous year, EV/EBIT (Enterprise Value to EBIT) was 11.47 — a change of -649.42% (lower).

EV/EBIT

-63.03

YoY

-649.42%

Last updated:

EV/EBIT (Enterprise Value to EBIT) of Medinice is 2025 -63.03 . EV/EBIT (Enterprise Value to EBIT) of Medinice was 2024 11.47 . It decreases by -649.42% lower compared to the previous year.

The Medinice EV/EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/EBIT
Date
EV/EBIT
Jan 1, 2019
-212.11 PLN
Jan 1, 2020
-148.53 PLN
Jan 1, 2021
-122.05 PLN
Jan 1, 2022
-85.45 PLN
Jan 1, 2023
-73.92 PLN
Jan 1, 2024
11.47 PLN
Jan 1, 2025
-63.03 PLN
Jan 1, 2026 (e)
3.38 PLN
The Medinice EV/EBIT history
YEAREV/EBITYoY
est3.38-105.36%
-63.03-649.42%
11.47-115.52%
-73.92-13.50%
-85.45-29.99%
-122.05-17.83%
-148.53-29.97%
-212.11-13.99%
-246.60-64.32%
-691.20-50.89%
-1,407.58—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Medinice Valuation

Details

Historical Valuation Multiples

ⓘ

Price-to-Earnings Ratio (P/E)

The P/E ratio divides Medinice's share price by its earnings per share. It tells you how many years of current earnings you are "paying for" when you buy the stock. A P/E of 20 means you pay $20 for every $1 of annual earnings. The S&P 500 historically trades at an average P/E of roughly 15–17. A P/E significantly above that may signal high growth expectations; one below may indicate undervaluation — or declining business quality.

Price-to-Sales Ratio (P/S)

The P/S ratio divides market capitalization by total revenue. Unlike the P/E ratio, it works even for companies that are not yet profitable, making it essential for evaluating high-growth firms. A P/S below 1.0 may indicate undervaluation, while ratios above 10 are typically reserved for fast-growing tech or SaaS companies with high expected future margins.

Price-to-EBIT Ratio

This ratio relates Medinice's market price to its operating earnings, excluding the effects of debt structure and tax jurisdiction. It is particularly useful for comparing companies across different countries or with different levels of leverage, because it focuses purely on operational profitability. Lower values suggest cheaper operational earnings.

How to Use This Chart

This chart plots Medinice's valuation multiples over time. Compare the current P/E, P/S, and P/EBIT to their own historical averages — if the current ratio is well below the multi-year average, the stock may be relatively cheap compared to its own track record. Combine this with industry comparisons: a P/E that looks high in absolute terms may be justified if Medinice grows earnings faster than its peers.

Medinice Stock analysis

What does Medinice do? Medinice SA generates revenue through the commercialization of medical device solutions, primarily focusing on cardiological and cardiosurgical products. The company's portfolio includes CathAIO, Cryoapplicator, Med-IConsole, Minimax, and Pacepress, which are sold globally via licensing agreements. These products target healthcare providers and medical device manufacturers seeking minimally invasive cardiology solutions. The firm collaborates with research centers in Poland and Europe to develop and commercialize inventions from its co-founders and acquired projects, emphasizing safe and minimally invasive medical technologies. Medinice SA's business model revolves around licensing its proprietary technologies to international partners for the production of medical devices. The company leverages its global potential projects to secure worldwide distribution agreements, ensuring revenue streams from multiple markets. By specializing in cardiology and cardio surgery, Medinice SA positions itself as a provider of innovative solutions for healthcare systems seeking advanced, minimally invasive procedures. The firm's revenue is derived from licensing fees and sales of its medical device solutions, with a focus on cardiological and cardiosurgical applications. Its products, such as CathAIO and Cryoapplicator, are designed to meet global demand for safe and minimally invasive treatments. Medinice SA's strategy involves partnering with research centers in Poland and Europe to enhance its portfolio, ensuring continuous innovation and market relevance in the medical device sector. Medinice is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Medinice stock

EV/EBIT (Enterprise Value to EBIT) of Medinice is -63.03 in 2025.

EV/EBIT (Enterprise Value to EBIT) of Medinice changed from 11.47 to -63.03, representing a -649.42% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/EBIT (Enterprise Value to EBIT) Medinice since 2006 – with annual values, charts, and detailed analysis.

The EV/EBIT ratio measures a company's enterprise value relative to its operating earnings. It accounts for debt, making it useful for comparing companies with different capital structures.

EV/EBIT = Enterprise Value / Earnings Before Interest and Taxes

To evaluate EV/EBIT (Enterprise Value to EBIT)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBIT (Enterprise Value to EBIT).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBIT (Enterprise Value to EBIT)'s Medinice with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Medinice

All Key Metrics — Medinice